Valuation: MannKind Corporation

Market Cap 1.03B 916M 846M 767M 1.43B 97.37B 1.46B 10.18B 4.03B 51.02B 3.85B 3.77B 161B P/E 2026 *
-16.7x
P/E 2027 * 1,437x
Enterprise Value 1.03B 916M 846M 767M 1.43B 97.37B 1.46B 10.18B 4.03B 51.02B 3.85B 3.77B 161B EV / Sales 2026 *
2.32x
EV / Sales 2027 * 2.02x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+4.93%
Current month-18.21%
1 month-3.04%
3 months-22.76%
6 months+18.15%
Current year-43.74%
1 week 3.01
Extreme 3.01
3.22
1 month 2.9
Extreme 2.895
4.22
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
25/9/26 Sell

Director

-39,051 0.0121%
10/9/26 Sell

Director

-33,558 0.0104%
7/8/26 Sell

Director

-39,051 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+4.93%-39.92%-23.13% 1.03B
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average +0.22%+2.20%+39.28%+124.49% 38.41B
Weighted average by Cap. +0.39%+2.72%+45.79%+142.39%

Financials

2026 *2027 *
Net sales 442M 395M 365M 330M 618M 41.95B 628M 4.39B 1.74B 21.98B 1.66B 1.62B 69.29B 507M 453M 419M 379M 710M 48.16B 721M 5.04B 1.99B 25.23B 1.9B 1.86B 79.55B
Net income -60.94M -54.42M -50.27M -45.56M -85.24M -5.79B -86.65M -605M -240M -3.03B -229M -224M -9.56B 1.18M 1.05M 972K 881K 1.65M 112M 1.68M 11.7M 4.63M 58.6M 4.42M 4.33M 185M
Net Debt - -
Projected Income Statement - Annual - MannKind Corporation
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
23/10/26 USD 3.190 -0.31% 3,089,446
22/10/26 USD 3.200 +4.92% 3,254,733
21/10/26 USD 3.050 -1.61% 2,798,921
20/10/26 USD 3.100 +0.32% 2,170,487
19/10/26 USD 3.090 +1.64% 2,463,049
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MannKind Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.190USD
Average target price
8.083USD
Spread / Average Target
+153.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MannKind Corporation
  1. Stock Market
  2. Stocks
  3. MNKD Stock